Sentence: A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon ( VEMUPLINT ) in advanced melanoma patients harboring the V600BRAF mutation .
Drug combination annotation:
[{'class': 'POS', 'spans': ['vemurafenib', 'cobimetinib', 'VEMUPLINT'], 'is_context_needed': True}]